Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Straus

Showing results (181-190 of 215) with videos related to

Pageof 22
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamideC S Portlock, J Qin, P Schaindlin, et al.
British Journal of Haematology|October 16, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantationDavid J Straus, Paul A Hamlin, Matthew J Matasar, et al.
Blood Advances|March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patientsJoachim Yahalom, Amy J Xu, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology|October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
American Journal of Hematology|May 19, 2020
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European studyPatrizia Mondello, Caterina Musolino, Irene Dogliotti, et al.
Blood|March 1, 2011
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETDavid J Straus, Jeffrey L Johnson, Ann S LaCasce, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Pageof 22

Showing results (181-190 of 215) with videos related to

Sort By:
Pageof 22
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamideC S Portlock, J Qin, P Schaindlin, et al.
British Journal of Haematology|October 16, 2014
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantationDavid J Straus, Paul A Hamlin, Matthew J Matasar, et al.
Blood Advances|March 31, 2021
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patientsJoachim Yahalom, Amy J Xu, Ariela Noy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
British Journal of Haematology|October 4, 2007
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor, Paul A Hamlin, Carol Portlock, et al.
American Journal of Hematology|May 19, 2020
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European studyPatrizia Mondello, Caterina Musolino, Irene Dogliotti, et al.
Blood|March 1, 2011
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETDavid J Straus, Jeffrey L Johnson, Ann S LaCasce, et al.
Blood Cancer Journal|May 22, 2019
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapseAnita Kumar, Fushen Sha, Ahmed Toure, et al.
Blood Advances|January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissueErel Joffe, Yan Leyfman, Esther Drill, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Pageof 22